Among patients with psoriasis who have active or recent cancer, biologic therapies show similar cancer progression or recurrence and serious infection rates compared with conventional systemic agents.
Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback